Gilead Sciences
Latest statistics and disclosures from Gilead Sciences's latest quarterly 13F-HR filing:
- Top 5 stock holdings are GLPG, ACLX, RCUS, ASMB, MRUS, and represent 95.78% of Gilead Sciences's stock portfolio.
- Added to shares of these 1 stock: ASMB (+$59M).
- Reduced shares in these 5 stocks: HOOK, ALLO, KLRS, IKNA, BRNS.
- Sold out of its positions in ALLO, HOOK, IKNA, KLRS, BRNS.
- Gilead Sciences was a net buyer of stock by $54M.
- Gilead Sciences has $1.8B in assets under management (AUM), dropping by 39.94%.
- Central Index Key (CIK): 0000882095
Tip: Access up to 7 years of quarterly data
Positions held by Gilead Sciences consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Gilead Sciences
Gilead Sciences holds 9 positions in its portfolio as reported in the September 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Galapagos Nv Spon Adr (GLPG) | 32.3 | $579M | 17M | 34.64 |
|
|
| Arcellx Common Stock (ACLX) | 30.8 | $552M | 6.7M | 82.10 |
|
|
| Arcus Biosciences Incorporated (RCUS) | 23.9 | $427M | 31M | 13.60 |
|
|
| Assembly Biosciences Com New (ASMB) | 6.4 | $115M | +103% | 4.5M | 25.60 |
|
| Merus N V (MRUS) | 2.4 | $43M | 453k | 94.15 |
|
|
| Tango Therapeutics (TNGX) | 2.3 | $41M | 4.9M | 8.40 |
|
|
| Kyverna Therapeutics (KYTX) | 1.4 | $25M | 4.1M | 6.00 |
|
|
| Xilio Therapeutics (XLO) | 0.4 | $7.7M | 9.1M | 0.84 |
|
|
| Leap Therapeutics Com New (LPTX) | 0.1 | $2.4M | 5.3M | 0.45 |
|
Past Filings by Gilead Sciences
SEC 13F filings are viewable for Gilead Sciences going back to 2024
- Gilead Sciences 2025 Q3 filed Nov. 13, 2025
- Gilead Sciences 2025 Q2 filed Aug. 14, 2025
- Gilead Sciences 2025 Q1 filed May 13, 2025
- Gilead Sciences 2024 Q4 filed Feb. 13, 2025